^
Association details:
| Biomarker: | PALB2 mutation |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug Class: | PARP inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
Excerpt:
Patients with BRCA1/2 or PALB2 mutations responding to platinum-based therapy can be considered for treatment with PARP inhibitors [V, B; ESCAT score: III-A].
